Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00426
|
|||||
| Drug Name |
Haloperidol
|
|||||
| Synonyms |
Aldo; Aloperidin; Aloperidin (TN); Aloperidol; Aloperidolo; Aloperidolo [DCIT]; Aloperidolo [Italian]; Aloperidon; Apo-Haloperidol; Bioperidolo; Bioperidolo (TN); Brotopon; Brotopon (TN); Dozic; Dozic (TN); Dozix; Duraperidol (TN); Einalon S; Einalon S (TN); Eukystol; Eukystol (TN); Fortunan; Galoperidol; H 1512; Haldol; Haldol (TN); Haldol La; Haldol Solutab; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidol (JP15/USP); Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]; Haloperidolum; Haloperidolum [INN-Latin]; Halopidol; Halopoidol; Halosten; Halosten (TN); Keselan; Keselan (TN); Lealgin compositum; Linton; Linton (TN);Novo-Peridol; McN-JR-1625; Mixidol; Pekuces; Peluces; Peluces (TN); Peridol; Pernox; Pms Haloperidol; R 1625; R-1625; Serenace; Serenace (TN); Serenase; Serenase (TN); Serenelfi; Sernas; Sernel; Sigaperidol; Sigaperidol (TN); Ulcolind; Uliolind; Vesalium
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H23ClFNO2
|
|||||
| Canonical SMILES |
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
|
|||||
| InChI |
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
|
|||||
| InChIKey |
LNEPOXFFQSENCJ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 52-86-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 375.9 | Topological Polar Surface Area | 40.5 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321347
, 10525411
, 11111260
, 11112116
, 11113356
, 11335829
, 11361068
, 11363755
, 11364802
, 11366317
, 11367364
, 11368879
, 11369926
, 11371416
, 11372966
, 11374119
, 11375526
, 11377041
, 11378093
, 11462040
, 11466143
, 11467263
, 11484972
, 11485805
, 11489084
, 11490264
, 11492385
, 11494675
, 12013409
, 14902191
, 17405145
, 24277917
, 26611764
, 26680483
, 26747061
, 26747062
, 26751574
, 26751575
, 26758862
, 29222690
, 443245
, 487337
, 4938
, 5123760
, 597375
, 7847204
, 7979526
, 8149365
, 8152250
, 855969
|
|||||
| ChEBI ID |
ChEBI:5613
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 33 microM | Baculovirus-infected insect cells-MDR1 | [3] | |
| References | ||||||
| 1 | Haloperidol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
| 3 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.